Navigation Links
Generic Onslaught Makes Drug Pricing Decisions More Critical Than Ever
Date:1/3/2008

NEW YORK, Jan. 3 /PRNewswire/ -- In an era of expanding competition from generics, expiring patent protection for many top-selling drugs, and a slowdown in new drug discoveries, there is very little margin for error in drug pricing decisions. A new report by Kalorama Information entitled Drug Pricing and Reimbursement Strategies: Preparing for the Coming Generic Onslaught gives pharmaceutical companies the information they need to reevaluate their pricing strategies to remain profitable in a changing marketplace.

Pharmaceutical sales reached $643.0 billion worldwide in 2006, increasing by 6.5% over the previous year, and global pharmaceutical companies have enjoyed a median profitability more than three times the average for all Fortune 500 companies. But companies will be challenged in the coming years: in addition to the onslaught of generics, which have increased their market penetration from 44% to 51.6% in the last couple of years, shrinking government and corporate healthcare budgets are putting pressure on the pricing strategies of pharmaceutical and biotech companies and reducing their margins. After eight years of double-digit growth, commercial prescription drug costs decreased to the single digits in 2003 and settled at a 4.8% growth rate in 2005.

"The golden years of monopolistic pricing in the United States are gone," notes the report's author, Joseph Constance. "Medicare Part D initiation, tiered managed care formulary systems, and the increasing clout of generic medicines are challenging margins now. Companies will have to adapt to survive, and pricing is one of the few levers they can pull."

Kalorama Information's report, Drug Pricing and Reimbursement Strategies: Preparing for the Coming Generic Onslaught provides considerable detail on this all-important area of pharmaceutical marketing strategy in the United States, Europe and Japan. It not only exposes the current business environment for pharmaceuticals, but also details strategies for specific results, including: gaining and defending market share through the cautious application of penetration pricing, enhancing brand loyalty with the 'bait and hook' tactic, as well as strategies for gaining new customers, improving margins and utilizing capacity. The report can be purchased directly from Kalorama Information by visiting http://www.kaloramainformation.com/Guide-Drug-Pricing-1422997, and is also available at http://www.MarketResearch.com.

About Kalorama Information

Kalorama Information supplies the latest in independent market research on medical markets. For more information, contact Tom Ehart at 240-747-3014 or tehart@marketresearch.com, or visit http://www.KaloramaInformation.com.


'/>"/>
SOURCE Kalorama Information
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Zyrtec Allergy Tablets(R) and Zyrtec Hives Relief Tablets(R)
2. Generic Prescription Drugs Show Increasingly Greater Use in Southeastern Pennsylvania
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Norvasc(R)
4. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lexapro(R)
5. New OIG Report Confirms Part D Plans Are Driving Generic Utilization
6. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lamictal(R)
7. Watson Files FDA Application for Generic YAZ(R)
8. Giant Eagle Expands Popular Generic Prescription Program and Now Offers 400 for $4
9. Barr Receives Tentative Approval for a Generic Version of Mirapex(R) Tablets, 0.125mg, 0.25mg, 0.5mg, 1mg and 1.5mg
10. Barrs Generic Version of Estrostep(R) Fe Tablets Approved
11. Amneal Pharmaceuticals & Indoco Remedies Finalize Long Term Joint Venture Agreement to Develop and Market Generic Ophthalmic Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... SC&H Group, a leading audit, tax, ... in its IT Advisory Services practice . Rossi is the third technology consulting ... for strategic IT guidance grows, and the practice continues to expand.     , Bringing more ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... offices in Tyler, has announced the latest beneficiary of their thriving community involvement ... nonprofit organization dedicated to fulfilling the dreams of terminally ill patients. Donations to ...
(Date:1/17/2017)... ... January 17, 2017 , ... Twelve (12) years ago the ... Education program forged a relationship built upon the foundation of sports safety. ... of both student members and certified members of the Athletic Trainers’ Society of ...
(Date:1/16/2017)... ... January 16, 2017 , ... Gym Source, America’s leading retailer of premium ... East Hanover, New Jersey. , “We are elated to be opening this new showroom,” ... is designed to give clients a seamless and motivating shopping experience.” , Every fitness ...
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... ... office , Antoine Dental Center, is currently offering complimentary consultations and financing for ... their teeth examined for bite irregularities and learn about their orthodontic options. Walk-in, ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... , January 17, 2017 ... 2016;11(Suppl. 1):2-4 ; http://www.touchneurology.com/articles/tailored-temperature-management-neurocritical-care ... ... Published recently in European Neurological ... touchNEUROLOGY, Catherine Amey reports that despite ...
(Date:1/17/2017)... -- Transparency Market Research has released a new market ... Alcohol and Others) Market - Global Industry Analysis, Size, Share, Growth, ... benzaldehyde derivative market was valued at US$ 1.37 Bn in ... expanding at a CAGR of 5.1 % from 2016 to 2024. ... Benzaldehyde derivatives are ...
(Date:1/17/2017)... BUDAPEST, Hungary , Jan. 17, 2017 /PRNewswire/ ... Plc. today announced positive results from Venus II, the second ... and safety of ulipristal acetate in women with abnormal bleeding ... ulipristal acetate is planned for the second half of 2017. ... Venus II supporting the efficacy and safety profile of ulipristal ...
Breaking Medicine Technology: